Valuation Charles River Laboratories International, Inc. Berne S.E.
Stocks
RV6
US1598641074
Biotechnology & Medical Research
|
End-of-day quote
Berne S.E.
28/09/2026
|
5-day change | 1st Jan Change | ||
| 243.60 CHF | +0.92% |
|
+6.87% | - |
Company Valuation: Charles River Laboratories International, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 18,941 | 11,138 | 12,252 | 9,520 | 10,023 | 14,063 | - | - |
| Change | - | -41.2% | 10% | -22.3% | 5.29% | 40.31% | - | - |
| Enterprise Value (EV) 1 | 21,366 | 13,616 | 14,622 | 11,565 | 11,946 | 16,176 | 15,697 | 15,303 |
| Change | - | -36.28% | 7.39% | -20.91% | 3.29% | 35.41% | -2.96% | -2.51% |
| P/E | 49.4x | 23.1x | 25.9x | 931x | -70x | 78.3x | 31.5x | 28.1x |
| PBR | 7.45x | 3.75x | 3.41x | 2.75x | 3.17x | 4.67x | 3.97x | 3.53x |
| PEG | - | 0.9x | -9.44x | -9.5x | 0x | -0x | 0x | 2.3x |
| Capitalization / Revenue | 5.35x | 2.8x | 2.97x | 2.35x | 2.5x | 3.59x | 3.51x | 3.32x |
| EV / Revenue | 6.04x | 3.42x | 3.54x | 2.86x | 2.98x | 4.13x | 3.92x | 3.62x |
| EV / EBITDA | 24.3x | 13.7x | 14.4x | 11.6x | 12.3x | 15.8x | 14.1x | 12.8x |
| EV / EBIT | 28.8x | 16.3x | 17.4x | 14.3x | 15x | 19.7x | 17.1x | 15.1x |
| EV / FCF | 40.2x | 46.2x | 40x | 23.1x | 23x | 50.9x | 25.6x | 32.2x |
| FCF Yield | 2.49% | 2.17% | 2.5% | 4.34% | 4.34% | 1.97% | 3.91% | 3.11% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 7.6 | 9.48 | 9.22 | 0.2 | -2.91 | 3.763 | 9.362 | 10.5 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 3,540 | 3,976 | 4,129 | 4,050 | 4,015 | 3,919 | 4,006 | 4,232 |
| EBITDA 1 | 879.5 | 990.9 | 1,013 | 996.1 | 971.5 | 1,024 | 1,112 | 1,192 |
| EBIT 1 | 742.1 | 834 | 838.8 | 805.9 | 793.9 | 821.9 | 916.6 | 1,014 |
| Net income 1 | 391 | 486.2 | 474.6 | 10.3 | -144.3 | 164.1 | 431.1 | 475.7 |
| Net Debt 1 | 2,425 | 2,477 | 2,370 | 2,046 | 1,923 | 2,112 | 1,633 | 1,239 |
| Reference price 2 | 375.34 | 218.92 | 238.84 | 186.16 | 203.66 | 294.59 | 294.59 | 294.59 |
| Nbr of stocks (in thousands) | 50,464 | 50,879 | 51,297 | 51,136 | 49,215 | 47,739 | - | - |
| Announcement Date | 16/02/22 | 22/02/23 | 14/02/24 | 19/02/25 | 18/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 34.14x | 6.12x | 18.32x | 0.95% | 4.91TCr | ||
| 34.9x | 3.36x | 14.48x | -.--% | 4.46TCr | ||
| -20.74x | 225.54x | -22.4x | -.--% | 4.32TCr | ||
| 48.07x | 5.56x | 30.53x | -.--% | 4.17TCr | ||
| 26.98x | 7.78x | 20.03x | 0.42% | 2.99TCr | ||
| 35.03x | 5.75x | 26.11x | -.--% | 1.72TCr | ||
| -61.09x | 9.99x | 243.97x | -.--% | 1.54TCr | ||
| 26.24x | 2.25x | 9.73x | 1.02% | 1.55TCr | ||
| Average | 15.44x | 33.29x | 42.60x | 0.3% | 3.21TCr | |
| Weighted average by Cap. | 20.34x | 42.68x | 26.48x | 0.29% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- CRL Stock
- RV6 Stock
- Valuation Charles River Laboratories International, Inc.
Select your edition
All financial news and data tailored to specific country editions
















